Stock 002566 JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jilin Jian Yisheng Pharmaceutical Co., Ltd.

Equities

002566

CNE1000011C3

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
6.86 CNY -3.65% Intraday chart for Jilin Jian Yisheng Pharmaceutical Co., Ltd. -3.79% -23.01%
Apr. 25 Jilin Jian Yisheng Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 18 Jilin Jian Yisheng Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 1,900 2,207 2,204 2,992 2,681 2,949
Enterprise Value (EV) 1 2,302 2,437 2,335 3,087 2,721 2,835
P/E ratio 27.5 x 28.8 x 27.5 x 31.2 x 32.3 x 31.1 x
Yield - 0.75% 0.45% 0.33% 0.62% 1.68%
Capitalization / Revenue 1.95 x 2.18 x 2.62 x 3.41 x 3.23 x 3.45 x
EV / Revenue 2.36 x 2.41 x 2.77 x 3.52 x 3.28 x 3.32 x
EV / EBITDA 15.9 x 16.2 x 17 x 20.1 x 21.2 x 21.2 x
EV / FCF 235 x 17.7 x 51.6 x 561 x 35.2 x 34 x
FCF Yield 0.43% 5.66% 1.94% 0.18% 2.84% 2.94%
Price to Book 1.02 x 1.14 x 1.1 x 1.44 x 1.24 x 1.32 x
Nbr of stocks (in thousands) 330,952 330,952 330,952 330,952 330,952 330,952
Reference price 2 5.740 6.670 6.660 9.040 8.100 8.910
Announcement Date 4/15/19 4/15/20 4/16/21 4/19/22 4/18/23 4/18/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 975.1 1,013 842.6 877.9 830 853.7
EBITDA 1 145.1 150.6 137.4 153.4 128.6 133.6
EBIT 1 105.7 109.1 97.4 114 88.73 88.53
Operating Margin 10.84% 10.77% 11.56% 12.98% 10.69% 10.37%
Earnings before Tax (EBT) 1 100.1 108.1 105 123.4 101.2 111.8
Net income 1 69.08 76.6 80.06 96.02 83.1 94.73
Net margin 7.08% 7.56% 9.5% 10.94% 10.01% 11.1%
EPS 2 0.2087 0.2314 0.2419 0.2901 0.2511 0.2862
Free Cash Flow 1 9.786 137.9 45.22 5.502 77.27 83.26
FCF margin 1% 13.61% 5.37% 0.63% 9.31% 9.75%
FCF Conversion (EBITDA) 6.75% 91.52% 32.92% 3.59% 60.1% 62.33%
FCF Conversion (Net income) 14.17% 179.98% 56.48% 5.73% 92.99% 87.89%
Dividend per Share - 0.0500 0.0300 0.0300 0.0500 0.1500
Announcement Date 4/15/19 4/15/20 4/16/21 4/19/22 4/18/23 4/18/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 402 230 131 95.2 40.4 -
Net Cash position 1 - - - - - 114
Leverage (Debt/EBITDA) 2.772 x 1.527 x 0.9534 x 0.6208 x 0.3145 x -
Free Cash Flow 1 9.79 138 45.2 5.5 77.3 83.3
ROE (net income / shareholders' equity) 4.4% 4.59% 4.28% 4.84% 3.97% 4.2%
ROA (Net income/ Total Assets) 2.54% 2.7% 2.3% 2.52% 1.9% 1.84%
Assets 1 2,722 2,836 3,480 3,815 4,369 5,148
Book Value Per Share 2 5.610 5.840 6.030 6.290 6.510 6.750
Cash Flow per Share 2 0.1200 0.1900 0.8700 0.6600 1.040 1.470
Capex 1 73.7 21.7 75.9 107 41.4 35.8
Capex / Sales 7.56% 2.14% 9.01% 12.2% 4.98% 4.19%
Announcement Date 4/15/19 4/15/20 4/16/21 4/19/22 4/18/23 4/18/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
JILIN JIAN YISHENG PHARMACEUTICAL CO., LTD. Stock Jilin Jian Yisheng Pharmaceutical Co., Ltd.
-23.01% 313M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002566 Stock
  4. Financials Jilin Jian Yisheng Pharmaceutical Co., Ltd.